Follow TNGB
Ozempic’s Mood Risks Raise Concerns Over Brain Effects
Full Story
New research warns that Ozempic and Wegovy, popular weight-loss drugs, may disrupt dopamine and increase risks of depression or suicidal thoughts. The drugs interact with genes tied to mood regulation, prompting scientists to urge caution for those with mental health vulnerabilities. The findings highlight unintended brain effects beyond the drugs’ benefits for weight and blood sugar.
Ozempic and Wegovy are GLP-1 drugs known for rapid weight loss. Their impact on dopamine, a key mood chemical, was previously understudied.
MEDIA REPORTING
See how news sources on all sides are covering this story.
Left 30% | Right 25% | Center 35% | Unrated 10%
The Context
The study identified interactions with genes like DRD3 and BDNF. These genes play critical roles in emotional stability and motivation.
Long-term use may heighten mood risks for those with low dopamine. Depression and suicidal thoughts are among the reported concerns.
Ozempic’s popularity surged for diabetes and obesity treatment. Its mental health side effects now demand closer scrutiny.
Some praise the drugs for transforming lives through weight loss. Others worry about unforeseen psychological consequences.
The findings echo earlier concerns about weight-loss drugs’ side effects. Regulatory agencies may now require updated warnings.
Scientists call for monitoring patients with mood disorder histories. Prescribing guidelines could shift to prioritize mental health screening.
Coverage Details
| Total News Sources | 40 |
| Left | 12 |
| Right | 10 |
| Center | 14 |
| Unrated | 4 |
| Bias Distribution | 35% Center |
Relevancy
Last Updated


